Home / Resources / Key Potential Drug Launches in 2025
Key Potential Drug Launches in 2025

These drugs represent new drug classes, major changes to standards of care, and/or large market opportunities.

PDF preview of the Key Potential Drug Launches 2025 Report.
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.
Related products
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline
Analyst using Datamonitor Healthcare for a market assesment.
Datamonitor Healthcare
Analysis and data tools for pharma market assessments without the guesswork
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape

Related resources

Citeline professional presenting the Q4 2024 Outlook Report provided by Biomedtracker.
SEP 30, 2024
Report
Commercial

Q4 Outlook Report: Key Industry Drugs, Devices & Deals

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q4 2024.

Stacks of coins arranged in ascending order with a white arrow and line graph overlay indicating growth
JUN 11, 2024
eBook
Commercial

Billion Dollar Blueprint: The Journey to Blockbuster Status

The industry’s top-selling drugs generate billions in revenues each year. Scrip analyzed data on nearly 200 blockbuster drugs, in search of the secret formula for creating the next pharmaceutical behemoth.

JP Morgan Post-Conference Report banner
MAR 21, 2024
Report
Commercial

JP Morgan Post-Conference Report

This report collates the daily presentation highlights from the JP Morgan Healthcare Conference in a single destination.

View all